The European Medicines Agency told doctors today that they can continue to prescribe Actelion‘s (VTX:ATLN) pulmonary arterial hypertension drug, Uptravi. The regulatory body initiated a safety review in January after 5 patients in France died and docs were asked to stop prescribing the drug.
Regulators reported that their review did not suggest an increase in mortality linked to Uptravi. The drug is Actelion’s 3rd best-seller, accounting for nearly 10% of the company’s 2016 sales.
Get the full story at our sister site, Drug Delivery Business News.
The post After review of patient deaths, European regulators OK Actelion’s Uptravi appeared first on MassDevice.